Sacituzumab govitEcan in THYroid Cancers

This trial is testing sacituzumab govitecan — an antibody-drug conjugate that delivers chemotherapy directly to cancer cells — in patients with advanced thyroid cancer that no longer responds to standard treatments, including radioactive iodine. **You may be eligible if...** - You are 18 or older - You have advanced differentiated thyroid cancer (Cohort A) that is refractory to radioactive iodine and has progressed on 1–3 prior drug therapies; OR anaplastic thyroid carcinoma (Cohort B) in first-line or after up to 1 prior treatment - Your cancer is measurable on scans - You are in reasonably good general health (ECOG 0–1) - Your blood counts, liver, and kidneys meet the required levels **You may NOT be eligible if...** - You have had more than 3 prior drug therapies (Cohort A) or more than 1 (Cohort B) - Your blood counts, liver, or kidney values are below acceptable thresholds Talk to your doctor to see if this trial is right for you.